Latest Information Update: 14 Feb 2005
At a glance
- Originator Merck & Co
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 31 Dec 2004 No development reported - Phase-I for Rheumatoid arthritis (unspecified route)
- 11 Mar 2004 Phase-I clinical trials in Rheumatoid arthritis (unspecified route)